Skip to Main Content

Paper Details

BET Bromodomain Inhibition Blocks an AR-Repressed, E2F1-Activated Treatment-Emergent Neuroendocrine Prostate Cancer Lineage Plasticity Program.
Clin Cancer Res
31
2021
AR, BET, BET bromodomain chromatin reader, BETi, BRD4, E2F1, NEPC, Neuroendocrine, Neuroendocrine Prostate Cancer, adenocarcinoma, androgen, androgen receptor, enzalutamide, enzalutamide-sensitive adenocarcinoma cell lines, enzalutamide-sensitive adenocarcinoma cells, neuroendocrine prostate cancer, patient, prostate cancer, t, t-NEPC, t-NEPC cells, t-NEPC lineage, t-NEPC tumor models, t-NEPC tumors, transcription factor, tumor, tumors
Author NameAffiliation
Dae Hwan KimKnight Cancer Institute, Oregon Health & Science University (OHSU)
Chelsea JenkinsKnight Cancer Institute, Oregon Health & Science University (OHSU)
Daniel J ColemanKnight Cancer Institute, Oregon Health & Science University (OHSU)
David SampsonKnight Cancer Institute, Oregon Health & Science University (OHSU)
Joshua UrrutiaKnight Cancer Institute, Oregon Health & Science University (OHSU)
Jacob SchwartzmanKnight Cancer Institute, Oregon Health & Science University (OHSU)
Himisha BeltranDana-Farber Cancer Institute, Harvard Medical School
Himisha BeltranDana-Farber Cancer Institute, Harvard Medical School
Colm MorrisseyUniversity of Washington
Ilsa ColemanDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
Peter S NelsonDivisions of Human Biology and Clinical Research, Fred Hutchinson Cancer Research Center
Eva CoreyUniversity of Washington
Rahul AggarwalHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Wassim AbidaMemorial Sloan Kettering Cancer Center
Felix Y FengHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Eric J SmallHelen Diller Family Comprehensive Cancer Center, University of California San Francisco
Daniel E SprattRogel Cancer Center, University of Michigan ann arbor
Daniel E SprattUniversity Hospitals, Case Western Reserve University
Armand BankheadRogel Cancer Center, University of Michigan ann arbor
Armand BankheadUniversity of Michigan ann arbor
Armand BankheadUniversity of Michigan ann arbor
Arvind RaoRogel Cancer Center, University of Michigan ann arbor
Arvind RaoUniversity of Michigan ann arbor
Arvind RaoUniversity of Michigan ann arbor
Arvind RaoRogel Cancer Center, University of Michigan ann arbor
Arvind RaoUniversity of Michigan ann arbor
Arvind RaoUniversity of Michigan ann arbor
Joshi J AlumkalKnight Cancer Institute, Oregon Health & Science University (OHSU)
Joshi J AlumkalUniversity of Michigan ann arbor
Joshi J AlumkalRogel Cancer Center, University of Michigan ann arbor
  • 1 - 31

Datasets